drugset / Trial / NCT00808288

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

NCT00808288

Phase 2 Completed 405 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)

Timeline

Start
2010-03
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-00610355 Small molecule 100 ug Oral
Subject PF-00610355 Small molecule 300 ug Oral
Subject PF-00610355 Small molecule 600 ug Oral
Comparator Salmeterol Other / unclassified 50 ug